Atara Biotherapeutics(US:ATRA) Prnewswire·2026-03-28 14:42Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc. and reminds investors of the May 22, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against the company [2][4]. Group 1: Allegations Against Atara Biotherapeutics - The complaint alleges that Atara and its executives violated federal securities laws by making false and/or misleading statements regarding manufacturing issues and deficiencies in the ALLELE study, which made FDA approval of the tabelecleucel BLA unlikely [4][9]. - It is claimed that the regulatory prospects of tabelecleucel were overstated, and the manufacturing issues subjected Atara to heightened regulatory scrutiny, jeopardizing ongoing clinical trials [4][9]. - The allegations suggest that these issues were likely to have a significant negative impact on Atara's business and financial condition, rendering the defendants' public statements materially false and/or misleading [4][9]. Group 2: Stock Price Impact - Following the announcement of a Complete Response Letter (CRL) from the FDA regarding the EBVALLO™ (tabelecleucel) BLA, Atara's stock price fell by $7.79 per share, or 56.99%, closing at $5.88 per share on January 12, 2026 [5][9]. Group 3: Legal Proceedings - The court-appointed lead plaintiff is defined as the investor with the largest financial interest in the relief sought by the class, who will direct and oversee the litigation on behalf of the putative class [6]. - Any member of the putative class may move the Court to serve as lead plaintiff or may choose to remain an absent class member without affecting their ability to share in any recovery [6].